Australia markets open in 8 hours 54 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
294.04-5.19 (-1.74%)
As of 11:05AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 77.71B
Enterprise value 69.30B
Trailing P/E 24.53
Forward P/E 21.51
PEG ratio (5-yr expected) 0.45
Price/sales (ttm)9.37
Price/book (mrq)6.51
Enterprise value/revenue 8.30
Enterprise value/EBITDA 16.77

Trading information

Stock price history

Beta (5Y monthly) 0.45
52-week change 353.42%
S&P500 52-week change 3-2.99%
52-week high 3305.95
52-week low 3176.36
50-day moving average 3281.76
200-day moving average 3247.28

Share statistics

Avg vol (3-month) 31.6M
Avg vol (10-day) 31.51M
Shares outstanding 5256.46M
Implied shares outstanding 6N/A
Float 8255.83M
% held by insiders 10.23%
% held by institutions 194.51%
Shares short (28 July 2022) 43.42M
Short ratio (28 July 2022) 42.31
Short % of float (28 July 2022) 41.33%
Short % of shares outstanding (28 July 2022) 41.33%
Shares short (prior month 29 June 2022) 43.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin 38.26%
Operating margin (ttm)37.43%

Management effectiveness

Return on assets (ttm)14.05%
Return on equity (ttm)30.24%

Income statement

Revenue (ttm)8.35B
Revenue per share (ttm)32.64
Quarterly revenue growth (yoy)22.50%
Gross profit (ttm)3.62B
Net income avi to common (ttm)3.19B
Diluted EPS (ttm)12.20
Quarterly earnings growth (yoy)1,109.70%

Balance sheet

Total cash (mrq)9.25B
Total cash per share (mrq)36.08
Total debt (mrq)847.3M
Total debt/equity (mrq)7.10
Current ratio (mrq)4.50
Book value per share (mrq)46.61

Cash flow statement

Operating cash flow (ttm)4.02B
Levered free cash flow (ttm)2.51B